Frontlight ResearchEarly access
Not yet recruitingPhase 2
SHIELD – Swift Hydrocortisone Intervention after trauma exposure
Key facts
- Who runs it
- Amsterdam UMC Stichting
- Where
- Netherlands4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 196 people, planned
- Started
- 1 Jan 2026
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional
- Record updated
- 13 July 2026
Who can take part
- Age
- 18 years to 64 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Age: 18 to 65
- Sex/gender: any
- Proficiency in Dutch
- Presented at ED as a result of a one-time incident involving injury as a result of an accident, physical or sexual violence or another kind of exceptional situation
Who cannot take part
- Psychiatric counterindications assessed through anamnesis
- Not able to give informed consent
- Not allowed to take hydrocortisone
- Practical exclusion criteria (e.g., no reliable access to telephone or internet)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The main objective is to investigate whether hydrocortisone, compared to placebo, leads to lower clinician-assessed PTSD symptomology 3 months after trauma.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Fit questions
- Built from 2025-523350-13-02, who can take part
- Record updated
- 13 July 2026